Real‐world relationship between blood biomarker‐based PhenoAge, metformin, and Alzheimer's disease

Read full text Summarise with VIRAT
Authors: Yi Shi, Anna Sun, Jing Xu, Yuedi Yang, Andrew J. Saykin, Feixiong Cheng, Pengyue Zhang
Cited by: 0
References: 49

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Abstract INTRODUCTION The biological aging process could be an important Alzheimer's disease (AD) pathogenesis. Metformin might be beneficial in anti‐aging and cognition and has mixed associations with AD and/or dementia. METHODS We used a US nationwide insurance claims dataset. We used Cox models to investigate the relationship between blood biomarker‐based PhenoAge and AD and PhenoAge‐stratified comparative AD risks between metformin and sulfonylureas. RESULTS We determined that a higher PhenoAge was associated with an increased risk of AD, and that metformin, compared with sulfonylureas, was associated with a reduced risk of AD only in individuals with a lower PhenoAge (hazard ratio: 0.42 to 0.50, p

Fields of Study & Subjects

Dementia and Cognitive Impairment Research Alzheimer's disease research and treatments Metabolism Diabetes and Cancer

Publication details

Journal / source
Alzheimer s & Dementia Translational Research & Clinical Interventions
Volume
12
Issue
2
Publication date
30 March 2026
Language
EN